Over 88% reduction in urinary incontinence episodes achieved in low dose cohort at 12 weeks Good tolerability with no systemic side effects First DNA medicine to selectively target, at the local level, a specific subtype of sensory neurons Fully vali... [6341 chars].. reed more
